Evenity (Romosozumab) Cost in Georgia 2026: Pricing, Insurance, and Savings

What Evenity Costs at Georgia Pharmacies in 2026

The manufacturer list price for a single monthly dose of Evenity (romosozumab-aqqg) is $1,825 in Georgia, identical to the national wholesale acquisition cost set by Amgen and UCB 1. A complete treatment course spans 12 monthly injections, placing the total sticker price near $21,900. No biosimilar or generic version exists as of May 2026.

Georgia retail pharmacies, including specialty pharmacies in Atlanta, Savannah, Augusta, and Macon, price Evenity at or very close to that list figure for cash-pay patients. Specialty pharmacies affiliated with health systems (Emory Specialty Pharmacy, Piedmont Pharmacy Services) sometimes negotiate slightly different acquisition costs, but those savings rarely pass through to uninsured patients at the counter.

The drug is classified as a physician-administered injectable by most payers, meaning it is often billed under medical benefit (not pharmacy benefit) when given in a clinic setting 2. This distinction matters. If your plan covers Evenity under medical benefit, you pay a coinsurance percentage rather than a flat copay, and your out-of-pocket exposure depends on whether you have met your annual deductible. Patients whose plans route Evenity through the pharmacy benefit typically face specialty-tier copays ranging from $150 to $500 per fill before any manufacturer assistance.

Georgia does not cap specialty drug copays at a state level, unlike states such as Colorado or Louisiana that have enacted copay accumulator reform laws. That gap means Georgia patients on high-deductible plans can face the full list price early in the calendar year.

Insurance Coverage for Evenity in Georgia

Most major commercial insurers operating in Georgia, including Anthem Blue Cross Blue Shield, Aetna, UnitedHealthcare, Cigna, and Ambetter, include Evenity on their formularies with conditions 3. Prior authorization is standard. The typical requirements include:

A confirmed diagnosis of osteoporosis with a DXA T-score of <-2.5 at the spine or hip, or a history of fragility fracture. Many plans also require documentation that the patient has tried or is ineligible for a bisphosphonate (alendronate or zoledronic acid) before approving Evenity, a step-therapy gate that adds weeks to the approval timeline.

Peer-to-peer review requests are common when initial prior authorizations are denied. Georgia physicians report that providing FRAX score documentation alongside DXA results increases first-pass approval rates. The AACE 2020 Clinical Practice Guidelines classify romosozumab as a first-line option for patients at "very high" fracture risk, which can support medical-necessity arguments when appealing denials.

For patients on employer-sponsored plans governed by ERISA (the majority of large-employer plans in Georgia), coverage decisions follow national formulary rules rather than Georgia-specific mandates. Self-insured employers can exclude Evenity entirely, and some do.

Georgia Medicaid and Evenity

Georgia Medicaid does not cover Evenity for osteoporosis as of 2026. The Georgia Department of Community Health's preferred drug list excludes romosozumab from its covered formulary for bone-health indications 4. Patients enrolled in Georgia Medicaid managed-care organizations (CareSource Georgia, Peach State Health Plan, Amerigroup) face the same exclusion.

This creates a gap for low-income postmenopausal women who meet clinical criteria for romosozumab but cannot access it through their insurance. The practical alternatives for Georgia Medicaid enrollees remain oral alendronate (covered, generic, approximately $4 per month), zoledronic acid infusion (covered in most plans with prior authorization), and denosumab (Prolia), which has Medicaid coverage in Georgia with step-therapy requirements.

Georgia expanded Medicaid eligibility in 2024 under a limited Section 1115 waiver, but the expansion did not change the formulary exclusions for specialty biologics like romosozumab. Patients who qualify for both Medicare and Medicaid (dual-eligible) may have Evenity covered under Medicare Part B, since Part B covers physician-administered injectables with a 20% coinsurance after the deductible.

How the Amgen/UCB Savings Card Works in Georgia

Amgen and UCB jointly offer the Evenity copay savings program, called "Evenity Complete." Georgia residents with commercial insurance can enroll online or through their prescribing physician's office. The program reduces out-of-pocket costs to as little as $5 per monthly injection, with a maximum annual benefit that typically ranges from $12,000 to $15,000 per year 5.

Key eligibility rules for Georgia patients: you must carry commercial (private) insurance, you cannot be enrolled in a government program (Medicare, Medicaid, Tricare, VA), and you must have a valid prescription for an FDA-approved indication. The savings card covers copay, coinsurance, and deductible costs up to the annual cap.

One caveat. Georgia has no state law prohibiting copay accumulator adjustment programs. Some Georgia-based commercial plans use accumulator programs that prevent manufacturer copay assistance from counting toward your deductible or out-of-pocket maximum. If your plan uses an accumulator, the Evenity savings card still lowers each monthly payment, but you may hit a "coverage gap" later in the year when the card's annual benefit runs out and your deductible has not advanced. Ask your benefits coordinator whether your plan uses a copay accumulator before starting treatment.

For uninsured Georgia patients, Amgen's patient assistance program (Amgen Safety Net Foundation) provides Evenity at no cost to qualifying individuals whose household income falls below 300% of the federal poverty level. The application requires income documentation and a physician signature.

Can You Get Compounded Romosozumab in Georgia?

Georgia permits 503A compounding pharmacies to operate under state Board of Pharmacy oversight, and some sources list compounded romosozumab as theoretically available through this pathway. The clinical reality is different.

Romosozumab is a humanized monoclonal antibody with a molecular weight of approximately 149 kDa 6. Monoclonal antibodies are produced through recombinant DNA technology in mammalian cell culture systems. A 503A compounding pharmacy cannot replicate this manufacturing process. Unlike small-molecule drugs such as compounded semaglutide or testosterone cypionate, where a pharmacy can source raw active pharmaceutical ingredient (API) powder and reconstitute it, no commercially available romosozumab API exists for compounders to purchase.

Any pharmacy claiming to sell "compounded romosozumab" in Georgia would be unable to produce a bioequivalent product. The FDA's guidance on biological products distinguishes biologics from small molecules and restricts compounding of complex biologics. Georgia patients should treat compounded romosozumab claims with skepticism. The only legitimate source is the branded Evenity product manufactured by Amgen.

Telehealth Prescribing of Evenity in Georgia

Georgia law permits telehealth prescribing of Evenity. The Georgia Composite Medical Board allows physicians to establish a patient-provider relationship via synchronous audio-video telehealth and prescribe injectable medications, including specialty biologics, following that encounter 7.

However, practical barriers exist. Romosozumab requires a DXA scan for diagnosis, baseline labs (calcium, vitamin D, renal function), and the subcutaneous injection itself requires either self-administration training or in-office administration. Most Georgia endocrinologists and rheumatologists use telehealth for the initial consultation and follow-up monitoring but require at least one in-person visit for DXA interpretation and first-dose observation.

Georgia-based telehealth platforms that specialize in osteoporosis management can coordinate with local imaging centers for DXA scans and arrange home-health nursing for injection administration. This hybrid model works well for patients in rural Georgia counties (where the nearest endocrinologist may be 60+ miles away in Atlanta, Augusta, or Savannah) but adds coordination complexity.

For patients considering telehealth-initiated Evenity, confirm that the prescribing provider can submit prior authorization to your insurer and that your plan covers telehealth-originated specialty prescriptions at the same benefit level as in-person prescriptions. Some Georgia commercial plans still apply differential cost-sharing to telehealth visits.

Clinical Evidence: Why Physicians Prescribe Romosozumab

Romosozumab works by a dual mechanism. It inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. Blocking sclerostin increases osteoblast activity (bone building) while simultaneously reducing osteoclast-mediated bone resorption 8. No other approved osteoporosis drug has this combined anabolic-antiresorptive profile.

The ARCH trial (N=4,093) compared 12 months of romosozumab followed by alendronate against alendronate alone in postmenopausal women with osteoporosis and a prior fracture. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fracture risk by 48% (relative risk reduction) compared to alendronate alone (p<0.001) 2. The FRAME trial (N=7,180) showed that 12 months of romosozumab reduced new vertebral fractures by 73% versus placebo at 12 months (0.5% vs. 1.8%, p<0.001) 4.

The 2020 AACE/ACE Guidelines state: "Romosozumab is recommended as initial therapy for patients at very high fracture risk, including those with recent fracture, T-score <-3.0, or high FRAX probability" 7. The Endocrine Society's 2019 guideline similarly positions romosozumab as a first-line anabolic agent for very-high-risk patients, noting that "sequential therapy with romosozumab followed by an antiresorptive agent provides greater fracture risk reduction than antiresorptive therapy alone" 9.

One significant consideration: the ARCH trial observed a higher rate of serious cardiovascular events in the romosozumab group versus alendronate (2.5% vs. 1.9%) during the first 12 months 2. This finding led the FDA to add a boxed warning advising against use in patients who have had a myocardial infarction or stroke within the preceding year 5. Georgia prescribers must conduct a cardiovascular risk assessment before initiating therapy.

Strategies to Lower Your Evenity Cost in Georgia

Several approaches can reduce what Georgia patients actually pay for romosozumab.

Enroll in Evenity Complete first. For commercially insured patients, this is the single most impactful step. Apply before your first injection so the savings card is active from dose one.

Request medical-benefit billing. If your physician administers Evenity in the office, it bills under your medical benefit (often with lower coinsurance than specialty pharmacy copays). Ask your provider's billing team which route produces a lower patient responsibility for your specific plan.

Use a specialty pharmacy affiliated with your insurer. Plans like Anthem and UnitedHealthcare require specialty medications to go through designated pharmacies (e.g., CarelonRx, Optum Specialty). Using the in-network specialty pharmacy avoids out-of-network penalties and sometimes triggers automatic prior authorization.

Appeal step-therapy denials with guideline citations. If your insurer denies Evenity because you haven't tried a bisphosphonate first, your physician can submit a letter citing the AACE 2020 guidelines 7, which recommend romosozumab as initial therapy for very-high-risk patients, bypassing step therapy on clinical grounds.

Check Medicare Part B coverage if eligible. Medicare Part B covers Evenity at 80% after the annual deductible when administered in a physician's office. The remaining 20% coinsurance on a $1,825 injection is $365 per dose. A Medigap supplemental plan (Plans C, F, or G are common in Georgia) can cover most or all of that coinsurance.

Apply to the Amgen Safety Net Foundation. Uninsured patients with household income below 300% of the federal poverty level ($46,800 for an individual in 2026) can receive Evenity at no cost through this program. Processing typically takes two to three weeks.

Patients starting Evenity should also confirm that a transition plan to an antiresorptive agent (denosumab or a bisphosphonate) is in place for after the 12-month romosozumab course ends. Abrupt discontinuation without follow-on therapy leads to rapid bone density loss, as documented in the FRAME extension data showing that patients who transitioned to denosumab maintained BMD gains while those who received placebo lost them 4.